Biotech & Medical AI Legal Services in China for Foreign Companies
Introduction
China’s biotech and medical AI sector is one of the fastest-growing in the world, fueled by massive government investment in healthcare innovation, a rapidly aging population, and the world’s largest healthcare market. For foreign biotech companies, medical device manufacturers, and AI-powered healthcare solution providers, China offers unprecedented opportunities—from access to large patient populations for clinical research to partnerships with world-class research institutions and a booming digital health market. However, the regulatory landscape for healthcare and life sciences in China is among the most complex and heavily regulated of any industry. From medical device registration with the National Medical Products Administration (NMPA) to strict data privacy requirements for health information and evolving regulations for AI-assisted diagnosis and treatment, foreign companies face a formidable array of legal and compliance challenges. Missteps can result in delayed product launches, regulatory penalties, or even permanent market exclusion. Geason Law Offices provides specialized legal services for foreign biotech and medical AI companies entering China, combining deep regulatory expertise with practical industry knowledge to help you navigate the path from market entry to commercial success.
Key Legal Challenges
Medical Device Registration and NMPA Approval
Bringing medical devices, including AI-powered medical software, to the Chinese market requires registration with the National Medical Products Administration (NMPA). The registration process varies significantly depending on the classification of the device—Class I (low risk), Class II (medium risk), or Class III (high risk)—with Class III devices requiring the most rigorous review, including clinical trials. For AI-powered medical devices, the NMPA has issued specific guidelines that address the unique characteristics of AI/ML-based products, including requirements for algorithm validation, training data quality, and post-market surveillance. Foreign companies face additional challenges, including the need to appoint a Chinese legal entity as the registration agent, comply with in-country clinical trial requirements, and navigate differences between Chinese and international regulatory standards. The registration timeline can range from several months for Class I devices to several years for Class III AI devices.
Clinical Trial Regulations and Ethics Review
Conducting clinical trials in China requires navigating a complex regulatory framework administered by the NMPA and the National Health Commission (NHC). Foreign companies must obtain clinical trial approval, register trials with the NMPA’s clinical trial registry, and obtain ethics committee approval from each participating institution. China’s clinical trial regulations have been reformed significantly in recent years to align more closely with international standards, but important differences remain. For medical AI products, clinical trial design presents unique challenges, including establishing appropriate endpoints, ensuring algorithm generalizability across diverse patient populations, and addressing regulatory concerns about algorithmic bias. Additionally, China has specific requirements for informed consent, data protection in clinical research, and adverse event reporting that foreign sponsors must comply with.
Health Data Compliance and Medical Data Security
Biotech and medical AI companies handle some of the most sensitive categories of personal data—health information, genetic data, and medical records—which are subject to heightened protection requirements under Chinese law. The Personal Information Protection Law (PIPL) classifies health information as sensitive personal information, imposing stricter requirements for consent, data minimization, and security. Additionally, the Human Genetic Resources Regulation governs the collection, preservation, utilization, and export of Chinese human genetic resources, requiring foreign companies to collaborate with Chinese institutions and obtain approval for research involving human genetic resources. The Medical and Health Data Security Management Measures add industry-specific data security requirements, including data classification, security assessment, and cross-border data transfer restrictions. For companies using medical data to train AI models, ensuring compliance with all applicable data regulations is a fundamental challenge.
AI-Assisted Diagnosis and Treatment Regulation
China has been actively developing regulations for AI-assisted medical diagnosis and treatment, recognizing both the potential benefits and risks of AI in healthcare. The NMPA has issued multiple guidelines on medical AI product review, establishing classification principles and review standards for AI-powered medical devices. Products that provide diagnostic or treatment recommendations are generally classified as medical devices and require NMPA registration, while products that provide only informational support may fall outside the scope of medical device regulation. However, the line between medical and non-medical AI in healthcare is not always clear, and companies must carefully analyze their product’s intended use and claims to determine regulatory requirements. The regulatory framework continues to evolve rapidly as new applications emerge, and companies must stay current with the latest guidelines and policy developments.
Intellectual Property Protection in Biotech and AI
Protecting intellectual property is critical for biotech and medical AI companies, whose value rests on proprietary technology, research data, and innovative methods. In China, biotech IP protection involves a complex interplay of patent law, trade secret law, and regulatory protections. Key issues include patent eligibility for biotech inventions (including gene sequences and therapeutic methods), patent term extensions for pharmaceutical products, data exclusivity for innovative drugs, and trade secret protection for proprietary research data and manufacturing processes. For medical AI, IP protection raises unique questions about the patentability of AI algorithms, copyright protection for software, and the intersection of IP protection with data privacy and regulatory requirements. Foreign companies also face challenges with IP enforcement in China, including the speed and effectiveness of patent litigation and the risk of IP theft by employees or partners.
Foreign Investment Restrictions and Market Access
China’s healthcare and life sciences sector includes several areas with foreign investment restrictions or special regulatory requirements. While many areas of biotech and medical device manufacturing are open to foreign investment, certain activities—such as clinical gene editing, stem cell therapy, and some categories of medical institutions—are restricted or prohibited. The Foreign Investment Negative List specifies which sectors are restricted or closed to foreign investment. For medical AI companies that provide telemedicine or internet healthcare services, additional regulatory requirements apply, including restrictions on foreign ownership of medical institutions and requirements for internet hospital licenses. Understanding these restrictions and structuring your market entry strategy accordingly is essential for foreign companies in the biotech and medical AI space.
How We Help
Medical Device Registration and Regulatory Strategy: We help you navigate the NMPA medical device registration process, from product classification and regulatory pathway selection to preparation of registration dossiers and coordination with testing institutions. For medical AI products, we provide specialized guidance on AI-specific review requirements and help you develop regulatory strategies that accelerate time to market.
Clinical Trial Compliance Advisory: We advise on clinical trial regulatory requirements in China, assist with trial application preparation and submission, help you navigate ethics review processes, and ensure compliance with informed consent, data protection, and adverse event reporting requirements. We also advise on cross-border clinical trial strategies and multi-center trial coordination.
Health Data and Genetic Resources Compliance: We develop comprehensive data compliance programs for biotech and medical AI companies, covering health data protection, genetic resources regulation compliance, medical data security, and cross-border data transfer mechanisms. We help you establish data governance frameworks that support research and product development while ensuring compliance with Chinese data regulations. Explore our data compliance services.
AI Medical Product Regulatory Strategy: We advise on the classification and regulation of AI-powered medical products, help you determine whether your AI tool qualifies as a medical device, and develop compliance strategies for both registered and non-registered medical AI applications. We also monitor evolving AI healthcare regulations and advise on their implications for your products. Learn more about algorithm filing and AI compliance.
IP Strategy and Protection: We develop comprehensive IP protection strategies for biotech and medical AI companies, including patent portfolio development, trademark registration, copyright protection for medical software, and trade secret protection programs. We also assist with IP enforcement, including patent litigation and administrative enforcement actions. Learn more about IP protection in China.
Market Entry Structuring and Compliance: We advise on optimal market entry structures for biotech and medical AI companies, taking into account foreign investment restrictions, regulatory requirements, and tax considerations. We handle entity establishment, assist with required licenses and approvals, and help you develop compliance programs for ongoing operations in China. Learn about China company incorporation.
Typical Engagements
Medical AI Device Registration Strategy: A US-based medical AI company with an AI-powered diagnostic imaging platform sought to register its product with the NMPA. We conducted a product classification analysis to determine the appropriate regulatory pathway, advised on the clinical evidence requirements for registration, helped them design a clinical trial protocol acceptable to Chinese regulators, identified and vetted local clinical trial partners, and guided them through the registration application process. We also advised on data compliance requirements for training and validating the AI model with Chinese patient data.
Biotech Market Entry and R&D Collaboration Structuring: A European biotech company planning to establish a research presence in China and collaborate with Chinese academic institutions engaged us to advise on market entry strategy and collaboration structuring. We advised on entity type selection and location, helped structure research collaboration agreements with Chinese universities to ensure IP ownership protection, advised on human genetic resources compliance for research involving Chinese patient samples, and drafted technology licensing and collaboration agreements.
Health Data Compliance Program for a Medical AI Startup: A Singaporean medical AI startup that uses Chinese hospital data to train its diagnostic algorithms needed to establish a comprehensive data compliance program. We conducted a data flow audit to identify all data collection, processing, and transfer activities, assessed compliance against PIPL, medical data security regulations, and human genetic resources requirements, helped them implement data de-identification and security measures, and established cross-border data transfer mechanisms for aggregated, non-identifiable research data.
Pharmaceutical IP Strategy and Enforcement: A Japanese pharmaceutical company with a portfolio of biologic drugs and drug delivery technologies needed to strengthen its IP position in China. We conducted an IP audit of their China portfolio, identified gaps in patent and trademark protection, developed a strategy for additional filings including patent term extensions, advised on data exclusivity protection, and assisted with enforcement actions against several generic competitors infringing on their patents. We also developed a trade secret protection program for their manufacturing process know-how.
Why Geason
Geason Law Offices brings deep expertise in China’s biotech and medical AI regulatory landscape, combined with practical understanding of the science, technology, and business of healthcare innovation. We work with foreign biotech companies, medical device manufacturers, digital health startups, and AI healthcare solution providers, helping them navigate China’s complex regulatory environment and build successful businesses.
Our team is led by He Qianggao (license: 14403201310092337), a senior China lawyer with over 10 years of experience advising foreign technology and life sciences companies on their China legal strategy. Mr. He has advised numerous international biotech and medical AI companies on NMPA registration, clinical trial compliance, data protection, and market entry structuring. His ability to bridge scientific understanding with legal expertise enables him to provide practical, technically informed advice.
As a bilingual law firm, we ensure seamless communication between your scientific, medical, and legal teams and Chinese regulatory authorities, research institutions, and business partners. Our lawyers are fluent in both English and Chinese and understand the cultural nuances that are critical for successful collaboration in the Chinese healthcare ecosystem.
Our focus on the AI industry chain gives us a unique perspective on medical AI regulation. We understand both the healthcare regulatory framework and the AI regulatory framework, and we help clients navigate the intersection of these two complex areas. This integrated approach is increasingly important as AI transforms healthcare delivery and new regulatory challenges emerge.
FAQ
How are AI-powered medical products regulated in China?
AI-powered medical products in China are regulated primarily through the medical device framework administered by the National Medical Products Administration (NMPA). Products that provide diagnostic or therapeutic decision support are generally classified as medical devices and require NMPA registration. The specific classification (Class II or Class III) depends on the intended use and risk level of the product. The NMPA has issued specific guidelines for AI medical device review that address algorithm validation, training data quality, performance evaluation, and post-market surveillance requirements. Products that provide only informational or educational support, without making diagnostic or treatment recommendations, may not be classified as medical devices. We can help you analyze your product’s intended use and determine the applicable regulatory pathway. Contact us for a regulatory assessment.
What are the requirements for conducting clinical trials of medical AI products in China?
Conducting clinical trials of medical AI products in China requires NMPA approval, registration in the NMPA clinical trial registry, and ethics committee approval from each participating institution. The specific requirements depend on the classification of the device and the type of trial. For AI-powered medical devices, additional considerations include ensuring that the training and validation datasets are representative of the Chinese patient population, establishing appropriate clinical endpoints that demonstrate clinical benefit, and addressing concerns about algorithmic bias and generalizability. The NMPA has also introduced pathways for innovative medical devices that can accelerate the review process for products with significant clinical value. We can help you design a clinical trial strategy that meets regulatory requirements while efficiently generating the evidence needed for registration.
How do data regulations affect medical AI companies working with Chinese health data?
Medical AI companies working with Chinese health data face multiple layers of regulation. The Personal Information Protection Law (PIPL) governs personal information, including health information which is classified as sensitive personal information requiring separate consent and enhanced protection. The Medical and Health Data Security Management Measures establish data security requirements specific to healthcare data, including data classification, security assessments, and breach notification. The Human Genetic Resources Regulation governs research involving human genetic resources, requiring foreign organizations to collaborate with qualified Chinese entities and obtain approval. Cross-border transfer of medical data is also subject to strict requirements, including security assessment for important data and standard contracts or certification for personal information. We can help you develop a data compliance framework that supports your AI development while ensuring regulatory compliance. Learn more about data compliance in China.
What IP protection strategies are available for biotech and medical AI in China?
Biotech and medical AI companies in China can use a combination of IP protection strategies. For biotech inventions, patents are the primary form of protection, covering compositions of matter, methods of treatment (with some limitations), and manufacturing processes. Patent term extensions are available for innovative drugs and medical devices to compensate for regulatory review time. For medical AI, protection options include software copyright, patents for novel algorithmic methods, and trade secret protection for proprietary algorithms and training data. Data exclusivity provides additional protection for innovative drug and medical device clinical trial data. The optimal strategy depends on the nature of your technology, your business model, and your competitive landscape. We can help you develop a comprehensive IP strategy that combines multiple forms of protection to maximize your IP value. Explore our IP protection services.
What are the foreign investment restrictions in China’s biotech and healthcare sector?
China’s Foreign Investment Negative List identifies sectors that are restricted or prohibited for foreign investment. In the biotech and healthcare sector, most areas of medical device manufacturing, pharmaceutical R&D, and biotech research are open to foreign investment. However, certain activities are restricted or prohibited, including: clinical gene editing and human stem cell research (prohibited for foreign investment), certain categories of medical institutions (restricted), and some types of genetic testing services (restricted). For medical AI companies that provide internet healthcare or telemedicine services, additional restrictions may apply, including requirements for medical institution licenses and restrictions on foreign ownership. The specific restrictions applicable to your business depend on your exact activities and business model. We can help you assess foreign investment restrictions and develop a market entry structure that complies with applicable regulations.
China’s biotech and medical AI market offers tremendous opportunities for foreign companies, but success requires careful regulatory planning and expert legal guidance. Whether you’re registering a medical AI product with NMPA, establishing research collaborations, or ensuring health data compliance, Geason Law Offices has the expertise to support you every step of the way. Contact us today to schedule a consultation with He Qianggao and discuss your biotech and medical AI legal needs in China.
Ready to Enter China?
We help foreign biotech and medical AI companies navigate China's legal and regulatory landscape. From entity setup to regulatory filing to IP protection, we provide clear, bilingual guidance every step of the way.
What you get from an initial consultation:
- A clear assessment of your China entry requirements
- A timeline and roadmap for your specific situation
- Transparent fee estimates with no surprises
- Answers to all your questions from lawyers who know the industry
No sales pitch. Just clear advice from lawyers who have helped companies like yours enter the Chinese market.